Phase 4 N=368 P4 (Pregabalin for Peripheral Posttraumatic Pain)
Neuralgia
Primary: Weekly Mean Pain Score at End of Treatment (Week 8) From Daily Pain Diary — 4.61; 5.23 score on a scale — p=0.010
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=50 Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder
Seasonal Affective Disorder
Primary: Sleep Satisfaction at Baseline and Measured Monthly, as Measured by the Pittsburgh Sleep Quality Index (PSQI) — 11.56; 11.45; 9.52; 8.67 scores on a scale
Phase 4 N=339 A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
Major Depressive Disorder
Primary: Change From Baseline to 4 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — 36.1; 36.0; -20.1; -19.9 units on a scale — p=0.88
Phase 4 N=1,470 Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients
Chronic Hepatitis B
Primary: Number of Participants Achieving HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) <1000 Copies/Milliliter at Week 48 — 341; 243; 584; 767 participants
Phase 4 N=533 Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B
Chronic Hepatitis B
Primary: Number of Participants Achieving HBV DNA ≤300 Copies/mL at Week 104 — 85; 403 participants
Phase 4 N=81 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
Macular Degeneration
Primary: Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) — 40; 7; 33 participants
Phase 4 N=418 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
Generalized Anxiety Disorder · Panic Disorder
Primary: Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of >=50%) in the Intent-to-treat…
Phase 4 N=377 Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS
Rhinitis, Allergic, Perennial
Primary: Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Treatment Periods of Active Drug Nasal Sprays Versus Placebos — -2.7…
Phase 4 N=23 Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients
Anemia
Primary: Serum Ferritin — 26.7 ng/mL
Phase 4 N=296 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Parkinson Disease · Depression
Primary: Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12 — -4; -5.9 Score on scale — p=0.0103
Phase 4 N=502 Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Cervical Dystonia
Primary: Treatment Assessment Scale (TAS), 4 Wks Post-injection Compared to Baseline (Time 0), Rating of Cervical Dystonia Symptoms — 0.9 points on a scale
Phase 4 N=155 Two Rizatriptan Prescribing Portions for Treatment of Migraine
Migraine
Primary: Number of Days With Migraine — 2.666; 2.738 Days
Phase 4 N=37 Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
Bacterial Infections · Eye Infections
Primary: Concentration of AzaSite and Vigamox in the Tear Fluid Across Six Time Points Ranging From 15 Minutes to 24 Hours Following Administration. — 16.485; 8.199; 4.007; 2.221…
Phase 4 N=116 Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery
Bacterial Infections · Eye Infections · Cataract Extraction
Primary: Conjunctiva Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population) — 40.4; 5.747; 33.55…
Phase 4 N=688 Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
HIV Infection
Primary: Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48 by Missing=Failure (M=F), Switched Included Analysis. — 67.5; 67.2 percentage of participants — p=0.913